Pub. Date : 1999 Apr
PMID : 10195935
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. | Niacin | apolipoprotein B | Homo sapiens |
| 2 | Utilizing human hepatoblastoma (HepG2) cells as an in vitro model, we have examined the effect of niacin on intracellular degradation of apoB and the regulatory mechanisms involved in apoB processing. | Niacin | apolipoprotein B | Homo sapiens |
| 3 | Niacin significantly increased apoB degradation in a dose- and time-dependent manner. | Niacin | apolipoprotein B | Homo sapiens |
| 4 | Niacin decreased inhibition of oleate-mediated apoB degradation. | Niacin | apolipoprotein B | Homo sapiens |
| 5 | These data indicate that niacin accelerates hepatic intracellular post-translational degradation of apoB by selectively reducing triglyceride synthesis (through inhibiting both fatty acid synthesis and fatty acid esterification to produce TG) without affecting ALLN-inhibitable protease- or MTP-mediated intracellular apoB processing, resulting in decreased apoB secretion and hence lower circulating levels of the atherogenic lipoproteins. | Niacin | apolipoprotein B | Homo sapiens |
| 6 | These data indicate that niacin accelerates hepatic intracellular post-translational degradation of apoB by selectively reducing triglyceride synthesis (through inhibiting both fatty acid synthesis and fatty acid esterification to produce TG) without affecting ALLN-inhibitable protease- or MTP-mediated intracellular apoB processing, resulting in decreased apoB secretion and hence lower circulating levels of the atherogenic lipoproteins. | Niacin | apolipoprotein B | Homo sapiens |
| 7 | These data indicate that niacin accelerates hepatic intracellular post-translational degradation of apoB by selectively reducing triglyceride synthesis (through inhibiting both fatty acid synthesis and fatty acid esterification to produce TG) without affecting ALLN-inhibitable protease- or MTP-mediated intracellular apoB processing, resulting in decreased apoB secretion and hence lower circulating levels of the atherogenic lipoproteins. | Niacin | apolipoprotein B | Homo sapiens |